Dergiler / The European Research Journal / 2017 / Cilt: 3 - Sayı: 2

Incidence of the genetic mutations in patients with coronary artery disease

Sayfa
145–151
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further studies are needed to support these findings.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Coronary artery disease (CAD) is the leading cause of mortality in the world.
📊
Temel Bulgular & Veri:The role of the factor V Leiden (FVL), protrombin gene (PT G20210A) and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in the development of CAD is controversial.
💡
Sonuç & Katkı:Further studies are needed to support these findings.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Methylenetetrahydrofolate reductase · polymorphism · genetic mutation

Abstract

Objectives. Coronary artery disease (CAD) is the leading cause of mortality in the world. It is a complex disorder resulting from the interaction between environmental risk factors and hereditary predisposition. The role of the factor V Leiden (FVL), protrombin gene (PT G20210A) and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in the development of CAD is controversial. In this study, we investigated the incidence of these polymorphisms in order to delineate their roles in the development of CAD in a tertiary University hospital. Methods. This study included 58 consecutive CAD patients. Diabetic and hypertensive patients were excluded. FVL, PT G20210A, and MTHFR (C677T, A1298C) mutations were investigated in all patients. Polymerase chain reaction and the amplification refractory mutation system were used to identify these polymorphisms. Results. Thirty-six men and 22 women were enrolled with an age ranging between 41 to 85 (mean age: 62.75±9.18 years). The heterozygous PT G20210A genotype was identified in 5 (8.6%) patients (2 males, 3 females). The heterozygous FVL genotype was found in 8 (13.8%) patients (6 males and 2 females). The incidence of homozygous MTHFR C677T and homozygous MTHFR A1298 carriers was found to be 17.2% and 8.6%, respectively. There were no significant differences in the distribution of polymorphisms according to gender (p>0.05). Conclusions. The FVL and PT G20210A polymorphisms most likely play a contributory role in the development of CAD. In contrast, the MTHFR C677T and MTHFR A1298C genotypes were not associated with a predisposition to the development of CAD. However, in compound MTHFR C677T/A1298C carriers, the presence of FVL or PT G20210 polymorphism may contribute the development of CAD. Further studies are needed to support these findings.

🔖

Bu Makaleye Atıf Yap

EKİM, M., EKİM, H. (2017). Incidence of the genetic mutations in patients with coronary artery disease. The European Research Journal, Cilt: 3 - Sayı: 2, 145–151. https://ajindex.com/articles/361172

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Ciftdogan DY, Coskun S, Ulman C, Tikiz H. The Factor V G1691A, Factor V H1299R, prothrombin G 20210A polymorphisms in children with family history of premature coronary artery disease. Coron Artery Dis 2009;20:435-9
  2. Ercan B, Tamer L, Sucu N, Pekdemir H, Camsari A, Atik U. Factor V Leiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease. Yonsei Med J 2008;49:237-43
  3. Hobikoglu GF, Akyuz U, Akyuz F, Ozer O, Guney D, Narin A, et al. Factor V Leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 2004;59:594-7
  4. Donmez Y, Kanadasi M, Tanriverdi K, Demir M, Demirtas M, Cayli M, et al. Prothrombin G20210A and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004;45:505-12
  5. Rahimi Z, Nomani H, Mozafari H, Vaisi-Raygani A, Madani H, Malek-Khosravi S, et al. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in Western Iran. Blood Coagul Fibrinolysis 2009;20:252-6
  6. Eskandari MK, Bontempo FA, Hassett AC, Faruki H, Makaroun MS. Arterial thromboemblic events in patients with the factor V Leiden mutation. Am J Surg 1998;176:122-5
  7. Poort SR, Rosendaal FR, Reitsma PH, and Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703
  8. Hotoleanu C, Trifa A, Popp R, Fodor D. The importance of homozygous polymorphisms of methylenetetrahydrofolate reductase gene in Romanian patients with idiopathic venous thromboembolism. Balkan Med J 2013;30:197-203
  9. Gurlertop HY, Gundogdu F, Pirim I, Islamoglu Y, Egerci N, Sevimli S, et al. Association between factor V Leiden mutation and coronary artery disease in the northeast region of Turkey. Blood Coagul Fibrinolysis 2007;18:719-22
  10. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vus HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50
  11. Boroumand M, Pourgholi L, Ziaee S, Anvari MS, Jalali A, Goodarzynejad H. The association between Factor V Leiden with the presence and severity of coronary artery disease. Clin Biochem 2014;47:356-60
  12. Dunn ST, Courtney R, Schechter E, Moore WE, Lee ET, Eichner JE. Role of Factor V L